Modified biological molecule is the joining of DNA molecules together from two different species and then is inserted into a host organism so as to produce a new genetic modified combination that adds value to healthcare and agriculture industry. Mostly used genetically modified products in healthcare are vaccines, monoclonal antibodies, and insulin, which have a huge market in the pharmaceutical industry. Enzyme production and recombinant proteins are mainly used in industrial purpose. National Academy of Medicine and National Academy of Sciences have taken initiative for involving new research in human gene-editing technique that will lead to the rising new treatment for the disorder.
Cipla and Roche have signed an agreement for sale and promotion of tocilizumab. The partnership will be beneficial to increase innovation and improve healthcare facilities. Recombinant Human growth hormone (hGH) was found to be of great progress in treating children. Various application of modified biological molecule in medicine is that it is used for gene therapy, synthesizing clotting factors, vaccination, and antiviral therapy. In agriculture, it is used for pesticide resistant crops, to grow genetically modified crops, to grow fruits with attractive colors (all this has been grown in artificial conditions). In pharmacology, it is used to produce artificial insulin, drug delivery at various targeted sites. Also, other applications of modified biological molecule market are to produce fluorescent fishes and glowing plants. The strategies for the treatment of various disorders are also improving by developing monitoring devices, diagnostic kits and new approaches in therapeutics. Large numbers of recombinant proteins are being used as an enzyme in various industries. Some of the major proteins used are proteins that are present in milk, and polymeric proteins are used in medical field and industries.
The major factor that fuels the growth of Modified biological molecule market is the increasing need to improve recombinant proteins. Recombinant proteins are the proteins that result in expression of recombinant DNA in living cells. This recombinant protein produces several folds that increase the demand for effective therapeutics for the treatment of disease. Also, various driving factors that grow the market are increasing use of genetically modified organisms, which are widely used in agriculture and this is one of the fastest and adopted innovations in last few years. Also, raising the burden of various chronic disorders and commercial success of biopharmaceutical industry are boosting the growth of this market. On the other hand, a high investment that is needed to establish manufacturing facilities of recombinant DNA, high complexity in producing recombinant DNA and adoption of genetically modified crops is less in developing countries which hamper the growth of the market.
The University of Pennsylvania has received approval from National Institutes of Health and the FDA in January 2018 to conduct first CRISPR trial to treat multiple myeloma, sarcoma and melanoma patients in U.S. University of Iowa and Columbia University Medical Center (CUMC) have used CRISPR for the retinitis pigmentosa (RP) to repair genetic mutation in 2016. There are 1.5 million cases of retinitis pigmentosa worldwide that affects retina to degrade and that leads to blindness. Sanofi Pasteur acquired Protein Sciences in 2017 with a strategy to add Flublok vaccine to its portfolio which is the recombinant protein-based vaccine approved by U.S. Food and Drug Administration.
This report provides analysis of modified biological molecule market that contains current industry trends, market size, market growth and demands, major players with their key strategies. It covers growth opportunities and market canvas in the coming years. The report has been made with an in-depth analysis along with inputs from the various industry experts. The research has been carried out with primary and secondary data sources and either supporting bottom-up or top-down approach.
Based on region, the global modified biological molecule market is segmented into North America, Europe, Asia-Pacific, and LAMEA. Regulatory structure of genetically engineered crops is improving in Japan. Soya and corn are majorly cultivated among other genetically modified crops in the U.S.
Some of the major players are Merck & Co., Pfizer Inc, Profacgen, GenScript, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, and Amgen Inc
Global Composite Testing Market Segmentation:
o Recombinant protein
o Therapeutics agents
• Non- Pharmaceutical
o Genetically modified crop
• Food and beverages
By End User
• Biochemical industry
• Research laboratories and academic institutes
• Biotechnology and pharmaceutical industry
• North America (U.S and Canada and rest of North America)
• Europe (Germany, France, Italy and Rest of Europe)
• Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
• LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)